Preoperative plasma levels of transforming growth factor ?1 strongly predict clinical outcome in patients with bladder carcinoma

Shariat, Shahrokh F.; Kim, JaHong; Andrews, Ben; Kattan, Michael W.; Wheeler, Thomas M.; Kim, Isaac Y.; Lerner, Seth P.; Slawin, Kevin M.

doi:10.1002/1097-0142(20011215)92:12<2985::aid-cncr10175>3.0.co;2-5

Cited by 81 publications

(42 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, overexpression of TGF-β ligands have been reported in most cancers, and high levels of these in tumor tissues and/or serum are associated with early metastatic recurrences and/or poor patient outcome (16)(17)(18)(19)(20)(21).…”

mentioning

confidence: 99%

Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression

Biswas¹,

Guix²,

Rinehart³

et al. 2007

J. Clin. Invest.

313

198

View full text Add to dashboard Cite

We investigated whether TGF-β induced by anticancer therapies accelerates tumor progression. Using the MMTV/PyVmT transgenic model of metastatic breast cancer, we show that administration of ionizing radiation or doxorubicin caused increased circulating levels of TGF-β1 as well as increased circulating tumor cells and lung metastases. These effects were abrogated by administration of a neutralizing pan-TGF-β antibody. Circulating polyomavirus middle T antigen-expressing tumor cells did not grow ex vivo in the presence of the TGF-β antibody, suggesting autocrine TGF-β is a survival signal in these cells. Radiation failed to enhance lung metastases in mice bearing tumors that lack the type II TGF-β receptor, suggesting that the increase in metastases was due, at least in part, to a direct effect of TGF-β on the cancer cells. These data implicate TGF-β induced by anticancer therapy as a prometastatic signal in tumor cells and provide a rationale for the simultaneous use of these therapies in combination with TGF-β inhibitors.

show abstract

mentioning

confidence: 99%

Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression

Biswas¹,

Guix²,

Rinehart³

et al. 2007

J. Clin. Invest.

313

198

View full text Add to dashboard Cite

show abstract

“…Elevated levels of plasma TGF-␤ are detected in patients with cancer, and in some cases, they predict for early metastatic recurrences (45)(46)(47)(48). Several anticancer therapies, many of which are ineffective against late tumors, can induce TGF-␤ systemically or in situ (49 -55).…”

Section: Discussionmentioning

confidence: 99%

Conditional Overexpression of Active Transforming Growth Factor β1 In vivo Accelerates Metastases of Transgenic Mammary Tumors

Muraoka-Cook¹,

et al. 2004

View full text Add to dashboard Cite

To address the role of transforming growth factor (TGF) ␤ in the progression of established tumors while avoiding the confounding inhibitory effects of TGF-␤ on early transformation, we generated doxycycline (DOX)-inducible triple transgenic mice in which active TGF-␤1 expression could be conditionally regulated in mouse mammary tumor cells transformed by the polyomavirus middle T antigen. DOX-mediated induction of TGF-␤1 for as little as 2 weeks increased lung metastases >10-fold without a detectable effect on primary tumor cell proliferation or tumor size. DOX-induced active TGF-␤1 protein and nuclear Smad2 were restricted to cancer cells, suggesting a causal association between autocrine TGF-␤ and increased metastases. Antisense-mediated inhibition of TGF-␤1 in polyomavirus middle T antigen-expressing tumor cells also reduced basal cell motility, survival, anchorage-independent growth, tumorigenicity, and metastases. Therefore, induction and/or activation of TGF-␤ in hosts with established TGF-␤-responsive cancers can rapidly accelerate metastatic progression.

show abstract

“…73,74 Several studies have shown that increased levels of circulating TGF-b1 were associated with cancer progression, occult and documented metastasis and biochemical progression in PCa patients. [74][75][76] However, other authors did not confirm such correlations. 77,78 Interleukin-6 (IL-6) is a cytokine with variable effects on immune and hematopoietic mechanisms.…”

Section: Urokinase Plasminogen Activation Systemmentioning

confidence: 91%

New circulating biomarkers for prostate cancer

Bensalah

Lotan

Karam

et al. 2007

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Preoperative plasma levels of transforming growth factor ?1 strongly predict clinical outcome in patients with bladder carcinoma

Cited by 81 publications

References 25 publications

Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression

Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression

Conditional Overexpression of Active Transforming Growth Factor β1 In vivo Accelerates Metastases of Transgenic Mammary Tumors

New circulating biomarkers for prostate cancer

Contact Info

Product

Resources

About